Christensenella timonensis Research & Development Service
As the search for Next-Generation Probiotics (NGPs) intensifies, the Christensenellaceae family has emerged as a "keystone" taxon for metabolic health. Specifically, Christensenella timonensis (C. timonensis) represents a frontier in Live Biotherapeutic Products (LBPs) targeting obesity and metabolic syndrome.
At Creative Biolabs, we bridge the gap between discovery and clinical application. Our specialized research platform offers end-to-end preclinical solutions—from anaerobic strain cultivation to efficacy testing in proprietary animal models—empowering pharmaceutical companies to accelerate their metabolic disease pipelines with confidence.
Overview: The "Lean" Microbe
C. timonensis is a Gram-negative, strictly anaerobic bacterium belonging to the family Christensenellaceae. First isolated from the human gut, this family is unique because it is highly heritable—meaning its presence is strongly influenced by host genetics—and it is consistently associated with a lean body mass index (BMI) and metabolic health.
Unlike traditional probiotics (e.g., Lactobacillus), C. timonensis is a next-generation candidate that functions as a bio-engineer of the gut ecosystem. It does not merely colonize; it actively modulates the metabolic output of the microbiome, influencing host lipid metabolism and systemic inflammation.
Key Biological Characteristics:
Taxonomy: Phylum Firmicutes, Family Christensenellaceae.
Metabolism: Strictly anaerobic; ferments carbohydrates to produce Short-Chain Fatty Acids (SCFAs), particularly acetate and butyrate.
Ecosystem Role: Often co-occurs with beneficial methanogens (like M. smithii), forming a cross-feeding network that optimizes energy homeostasis.
Our Preclinical Services
We offer a modular service platform designed to overcome the challenges of working with strict anaerobes.
Anaerobic Culturing & Strain Banking
Strict Anaerobic Isolation: Utilization of anaerobic chambers for the isolation, purification, and banking of C. timonensis from clinical samples.
High-Density Fermentation: Optimization of culture media (e.g., modifying carbon sources like xylose/peptone) to achieve high viable counts for animal dosing.
Co-Culture Models: Studying the interaction between C. timonensis and intestinal epithelial cells (Caco-2/HT-29) to measure barrier function enhancement (TEER assays).
Metabolic Profiling: LC-MS analysis of supernatant to quantify SCFA production and bile acid transformation capabilities.
Diet-Induced Obesity (DIO) Mice: Evaluation of C. timonensis intervention on weight loss, fat mass reduction, and glucose tolerance in mice fed a high-fat diet.
Germ-Free (GF) Mouse Colonization: Monocolonization or humanized microbiota transplantation studies to isolate the specific impact of the strain on host phenotype.
Histopathology: Analysis of adipose tissue inflammation and liver steatosis (NAFLD/NASH markers).
Christensenella is a Gram-negative, strictly anaerobic genus of bacteria first discovered in the human gut. Christensenella massiliensis was isolated from human stool specimen from a 66-year-old patient.
Current research into Christensenella timonensis focuses heavily on metabolic disorders. It is being investigated as a cornerstone therapy for conditions where the "Western Diet" and dysbiosis have compromised host health.
Target Indications
Obesity & Weight Management: Studies suggest an inverse correlation between the abundance of Christensenella and BMI. It is being developed to treat diet-induced obesity (DIO).
Type 2 Diabetes (T2D): By modulating glucose homeostasis and insulin sensitivity.
Metabolic Syndrome: Addressing the cluster of conditions, including hypertension, high blood sugar, and abnormal cholesterol levels.
Inflammatory Bowel Disease (IBD): Due to its potential to strengthen the gut barrier and reduce systemic inflammation.
Mechanisms of Action (MoA)
Research indicates that C. timonensis exerts therapeutic effects through three primary pathways:
Restoration of Gut Barrier Integrity: It promotes the expression of tight junction proteins, reducing "leaky gut" and preventing Lipopolysaccharide (LPS) translocation into the bloodstream (endotoxemia).
Modulation of Lipid Metabolism: It alters the bile acid pool in the gut, which signals the host liver to regulate fat storage and oxidation.
SCFA Production: It produces acetate and butyrate, critical metabolites that regulate satiety hormones (GLP-1) and reduce adipose tissue inflammation.
Why Choose Us?
"Anaerobe-First" Expertise
Christensenella timonensis is notoriously difficult to culture due to its extreme sensitivity to oxygen. Our facility is equipped with industrial-grade anaerobic workstations and bioreactors that ensure strain viability from the petri dish to the lyophilizer.
Translational Focus
We don't just generate data; we generate IND-enabling data. Our study designs are aligned with guidelines for Live Biotherapeutic Products (LBPs), focusing on identity, potency, purity, and safety.
Customizable Disease Models
We understand that metabolic syndrome is complex. We offer customizable diet protocols (Western diet, High-Fructose, Choline-Deficient) to mimic specific patient phenotypes relevant to your drug's target profile.
Accelerate Your Microbiome Pipeline Today
The correlation between Christensenella timonensis and metabolic health represents one of the most promising opportunities in the LBP market today. However, the path from a promising correlation to a viable drug candidate is paved with technical challenges. Do not let the complexities of anaerobic culturing or model validation slow your progress. Partner with a CRO that understands the unique biology of Christensenella. Whether you need a proof-of-concept study in mice or a detailed mechanism-of-action analysis, we are ready to advance your therapeutic asset.
While currently in the preclinical research phase, the Christensenellaceae family is a commensal group found in healthy humans. Early safety assessments suggest it is non-pathogenic, but thorough toxicological studies (which we provide) are required for regulatory approval.
Can you help with the manufacturing of this strain for clinical trials?
Currently, our manufacturing services focus on preclinical scale-up (non-GMP). However, we can develop the Master Cell Bank (MCB) and optimize the upstream process (media/fermentation conditions) to facilitate a smooth tech transfer to a CDMO for GMP production.
How do you ensure the viability of the strain during shipping?
We utilize advanced lyophilization (freeze-drying) cycles with proprietary cryoprotectants to ensure high viability. We ship products on dry ice with temperature monitoring to ensure stability upon arrival.
Do you offer intellectual property (IP) support for new strains isolated?
Yes. If we isolate a novel strain from your provided samples, we offer full genomic characterization and patent deposition support. You retain full ownership of the IP.
Online Inquiry
For Research Use Only. Not intended for use in
food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
